TX-PLANVIEW
1.5.2024 15:01:33 CEST | Business Wire | Press release
Planview, the leading end-to-end platform for Strategic Portfolio Management (SPM) and Digital Product Development (DPD), today announced a series of platform innovations designed to accelerate the speed and impact of transformation by connecting project and product initiative data across the enterprise. These innovations enable bi-directional visibility and governance to create tighter alignment between strategies and teams, harness AI to enhance predictability and strategic decision-making, and deliver personalized user experiences to uplevel productivity.
“Organizations today are struggling with data sprawl and misalignment across their disparate teams and tools, with negative impact to the speed and success of their transformation efforts,” said Louise K. Allen, Chief Product Officer. “The platform innovations released today change how the enterprise leverages and connects data, transitioning it from an unusable repository to an invaluable asset. We are breaking down data silos by connecting strategic priorities and the teams delivering the work, enabling organization-wide visibility to keep outcomes front and center.”
Accelerate Outcomes with Comprehensive Data Visibility and Personalization
Introducing Planview.Me™, an easy-to-use, personalized platform experience designed to bring data, insights, and work together into a single view. With Planview.Me, teams and individuals across roles and personas can:
- Create configurable, unique views based on status, progress, stakeholder needs, and other data-oriented use cases.
- Reduce platform clicks to surface the right information at the right time with clear actions in a single view, for an improved user experience.
- Take action, investigate, respond, and react with a single click, increasing efficiency by having relevant data available at your fingertips.
- Bring data and insight transparency into all decisions and to all decision-makers within the organization.
Uplevel Your Productivity with Actionable AI-Insights and Expert Guidance
Planview® Copilot is now available across Strategic Portfolio Management, Enterprise Agile Planning (EAP), Value Stream Management (VSM), and Digital Product Development solutions, including the Planview® Portfolios, Planview® Viz, Planview® AdaptiveWork, and Planview® AgilePlace products.
First introduced as an Early Access release in September 2023, Planview Copilot users can:
- Converse with and question their data using natural language to glean insights, derive recommendations based on best practices, and inform strategic decisions.
- Instantly tap into decades of Planview knowledge, best practices, and key learnings.
- Surface hidden insights and delivery risks across multiple initiatives, value streams, products, and projects.
- Increase productivity by analyzing and synthesizing vast amounts of data in seconds.
Further boosting Planview’s AI-enabled platform capabilities, Planview is strengthening its early-warning systems with additional sentiment analysis and aggregation across key products, including Planview Portfolios, Planview® AgilePlace, and Planview® ProjectPlace. Sentiment analysis can:
- Create sentiment scores based on emotional tone across multiple comments and text entries to provide an overview of product, project, or work health.
- Analyze trends over time to understand whether large bodies of work reflect positive, neutral, or negative sentiments.
- Accurately reflect the status of the work outside of traditional red, amber, and green indicators.
“Connecting value stream data is a critical first step in creating the visibility needed to understand where your organizational challenges lie,” says Mik Kersten, Chief Technology Officer. “With Planview Copilot’s new skills and our robust early warning systems now embedded across the entire Planview Platform, we are empowering organizations with more than visibility – we are giving them the actionable insights that will shape their strategic decisions, drive productivity, and accelerate time to value for digital transformations.”
Redefine How Work Gets Done with Less Disruption and More Enterprise-wide Work Connectivity
With enhanced connectivity between Planview Portfolios and Planview ProjectPlace, Planview is bringing traditionally ungoverned work into the purview of portfolio leadership to ensure alignment, oversight, and governance while empowering teams to deliver projects with easy-to-use capabilities like Gantt, kanban, and document storage, in discrete workspaces with no manual status reporting. This enhancement drives greater team autonomy, allowing teams to continue working within their projects and programs without disruption, while providing leadership with the right level of visibility and oversight.
Finally, Planview introduces the Planview® Universal Connector, a strong addition to the 60+ software tool connectors it already has available. The Universal Connector enables organizations to automate and seamlessly integrate their third-party or homegrown software development tools directly into the Planview® Platform. By unlocking data siloed in disparate software delivery tools, data and work can flow directly into the Planview Platform, increasing data visibility and keeping productivity high without disrupting the native work and workflow processes of the delivery teams.
Additional Resources:
- Learn more about the Planview Platform
- Check out the Platform Demo to learn more about Planview.Me and Planview Copilot
- Learn more about Planview Copilot
- Register to attend Planview Accelerate on May 14-15, 2024, to learn more about Planview’s approach to Strategic Portfolio Management, Digital Product Development, Data, Generative AI, and Connected Work
About Planview
Planview is the leading end-to-end platform for Strategic Portfolio Management (SPM) and Digital Product Development (DPD), enabling organizations to plan and deliver large-scale digital transformation initiatives. Planview empowers organizations to improve time-to-market and predictability, increase efficiency to unlock capacity, and ensure their most strategic product and project initiatives deliver the desired business outcomes. Our connected platform of solutions underpins the business and digital transformations of more than 4,500 customers and 2.7 million users globally, including 59 of the Fortune 100. Headquartered in Austin, Texas, Planview has over 1,400 employees worldwide.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240429197434/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom